In the finale of this three-part series on clinical finance, IGM Biosciences Vice President, Financial Planning & Analysis Chris Chan discusses how to leverage the role of clinical finance for clinical trial success.
In part two, IGM Biosciences Vice President, Financial Planning & Analysis Chris Chan explains just how important the role of clinical finance can be in bringing harmony and success into clinical research.
IGM Biosciences Vice President, Financial Planning & Analysis Chris Chan explains why the role of clinical finance can be so challenging to define, uphold, and even defend in the world of clinical research.
DTP and home treatment studies can get expensive — and be a hassle to patients — if the IRT element isn’t well planned for during trial design. In their SCOPE Summit presentation, Irina Grishina and Kelsey Kern of CSL Behring plan to share their personal anecdotes and lessons learned from both types of trials as they pertain to IRT.
Tokenization in clinical trials is still a new concept to many sponsors — and their patients who are volunteering for the studies. At his SCOPE Summit presentation, Tom Dougherty of Pfizer will explain this concept and discuss what trials are a fit.
Mary Arnould, senior director, program management/RBM lead, Clinical Science Operations at Astellas, talks about her SCOPE Summit 2024 presentation called “COVID-19 Pandemic Impact on Risk-Based Quality Management.”
Accenture Applied Life Science Solutions' Raj Bandaru, Ph.D. breaks down, summarizes, and shares detailed insight on the recent FDA Draft Guidance that addresses “Rare Diseases: Considerations for the Development of Drugs and Biological Products.”